Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT02718001
Active, not recruiting Not applicable

Edwards EVOQUE Eos MISCEND Study

NCT02718001 · tracked via the Priya Life Science Israel tracker
Sponsor
Edwards Lifesciences
Phase
Not applicable
Started
2015-02-06
Last updated
2026-04-13

Condition(s) studied

Mitral Valve Regurgitation (Degenerative or Functional)

Investigational drug(s) / intervention(s)

Edwards EVOQUE Eos Mitral Valve Replacement System

Edwards EVOQUE Eos Mitral Valve Replacement System: Replacement of the mitral valve through a transcatheter approach

Study summary

Study to evaluate the safety and performance of the Edwards EVOQUE Eos mitral valve replacement system

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Clinically significant, symptomatic mitral regurgitation * High risk for open-heart surgery * Meets anatomical criteria Exclusion Criteria: * Unsuitable anatomy * Patient is inoperable

Primary outcome measure(s)

Trial sites (19)

FacilityCityRegionStatus
Sutter Mills-Peninsula Burlingame California
Cedars-Sinai Medical Center Los Angeles California
Kaiser Permanente San Francisco San Francisco California
Emory University Hospital/Emory University Hospital Midtown Atlanta Georgia
Northwestern University Chicago Illinois
St. Vincent Heart Center Indianapolis Indiana
Beth Israel Deaconess Medical Center Boston Massachusetts
Morristown Medical Center Morristown New Jersey
St. Francis Hospital Roslyn New York
Cleveland Clinic Cleveland Ohio
Oregon Health & Science University Portland Oregon
The Hospital of the University of Pennsylvania Philadelphia Pennsylvania
The University of Texas Health Science Center at Houston/Memorial Hermann Texas Medical Center Houston Texas
The Heart Hospital Baylor Plano Plano Texas
Intermountain Medical Center Murray Utah
University of Virginia Health System Charlottesville Virginia
St. Paul's Hospital Vancouver British Columbia
Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Université Laval Québec Canada
St. Michael's Hospital Toronto Canada

More Edwards Lifesciences trials in Israel

ALTERRA Post-Approval Study Active, not recruiting
PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis Active, not recruiting
COMPASSION S3 Post-Approval Study Active, not recruiting
TRISCEND II Pivotal Trial Active, not recruiting
EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02718001 on ClinicalTrials.gov ↗ ← All trials in Israel